13F filing recap · Q3 2024

What did Patient Capital Management buy in Q3 2024?

Reported stock-position changes between this filing and the previous one.

Stock value

$2.04B

Positions

Estimated turnover

17.2%

Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.

Quarter in review

Patient Capital Management opened new positions in Qxo and Dave & Buster’s Entertainment, while exiting Uber Technologies entirely. The firm substantially added to Royalty Pharma, Sofi Technologies, and the SPDR S&P 500 ETF Trust, and trimmed Western Alliance Bancorporation, JPMorgan Chase, and Everi Holdings significantly. It also made modest reductions across Amazon, Alphabet, Citigroup, Expedia, Meta Platforms, and others.

New positions

QXOQxo, Inc.$122.09Mreported value+7.74M shares PLAYDave & Buster’s Entertainment, Inc.$44.29Mreported value+1.30M shares

Increased positions

PPLIIac Inc.$89.53Mreported value+66.1K shares+4.1%NVDANvidia Corp$73.92Mreported value+2.9K shares+0.5%RPRXRoyalty Pharma Plc$57.75Mreported value+616.8K shares+43.3%UALUnited Airlines Holdings, Inc.$57.38Mreported value+12.1K shares

Reduced positions

AMZNAmazon.com Inc$116.52Mreported value-6.4K shares-1.0%GOOGLAlphabet Inc.$98.80Mreported value-5.5K shares-0.9%CCitigroup Inc$96.52Mreported value-121.3K shares-7.3%EXPEExpedia Group, Inc.$95.82Mreported value-68.6K shares

Exited positions

UBERUber Technologies, Inc.$1.90Mprior reported value-26.2K shares-100.0%